Lv7 热心小伙伴
5001 积分 2021-08-06 加入
呱
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies
14天前
已完结
Triplet Therapies in Chronic Lymphocytic Leukemia
24天前
已完结
Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs
24天前
已完结
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia
1个月前
已关闭
Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
1个月前
已完结
Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China
1个月前
已完结
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia
1个月前
已完结
Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia
1个月前
已关闭
Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment
1个月前
已完结
Determination of Orelabrutinib in Human Plasma Using LC-MS/MS
1个月前
已完结
皖公网安备34019202002308
